Figure 2 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

<p>Median number of (<b>A</b>) total, (<b>B</b>) existing, and (<b>C</b>) new expanded T-cell clones at the end of cycle 1 across the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms. A pairwise Wilcoxon rank-sum test performed on all available data per arm; <i>P</i> values adjusted for multiple comparisons using the Benjamini–Hochberg procedure. Significant differences between treatment arms are notated as follows: *, 0.05 ≥ <i>P</i> > 0.01; **, 0.01 ≥ <i>P</i> > 0.001; ***, 0.001 ≥ <i>P</i> > 0.0001; ****, 0.0001 ≥ <i>P</i> . Nonsignificant differences between treatment arms are unlabeled. The lower and upper hinges of each boxplot are at the first and third quartiles. Boxplot whiskers extend to the most extreme value no further than 1.5 × IQR. Horizontal bar in each boxplot is at the median value. Analysis data cutoff: November 06, 2020. D, durvalumab monotherapy; T, tremelimumab monotherapy.</p>